Weight Loss Injections at Med Spas: Complete Compliance Checklist for 2026

Weight loss injection programs have become a core revenue driver for med spas nationwide. GLP-1 medications like semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound), along with B12, MIC, and liraglutide injections, are generating significant patient demand and practice revenue.

But this growth has attracted intense regulatory attention. The FDA's 2025 enforcement actions against compounded GLP-1 pharmacies sent shockwaves through the industry. State medical boards have increased audits of weight loss practices. And the DEA has issued warnings about GLP-1 prescribing patterns that suggest weight loss without medical justification.

If you're offering weight loss injection services, use this compliance checklist to assess where your practice stands — and what needs to be addressed before regulators come knocking.

Section 1: Prescribing and Clinical Foundation

✅ Licensed Prescriber on File

Every GLP-1 prescription must come from a licensed prescriber (MD, DO, NP with prescriptive authority, or PA under appropriate supervision). The prescriber's license must be verified as current and unrestricted in your state. Document the prescriber's license number in each patient chart.

✅ Medical Director With Standing Orders

Your medical director must have signed standing orders specifically authorizing GLP-1 prescribing by mid-level providers. These standing orders must define: eligible medications, patient selection criteria, dose ranges, escalation protocols, and when physician consultation is required. Unsigned or undated standing orders are non-compliant.

✅ Good Faith Exam (GFE) for Every Patient

A documented GFE is required before the first prescription for any GLP-1 medication. The GFE must be conducted by a licensed prescriber via synchronous, real-time interaction (not an asynchronous online questionnaire). Key elements to document:

• Current height, weight, and BMI calculation
• Presence of qualifying comorbidities (for patients BMI 27–29.9)
• Contraindications screening (MTC history, MEN 2, pancreatitis history)
• Current medications and potential interactions
• Lab results reviewed or ordered
• Clinical rationale for the specific medication chosen
• Alternative treatments discussed
• Prescriber's electronic or wet signature with date

✅ Eligibility Criteria Defined in SOP

Your weight loss SOP must define exactly who qualifies for each medication. For Wegovy/Zepbound, eligibility requires BMI ≥ 30 OR BMI ≥ 27 with at least one weight-related comorbidity. Prescribing to patients who don't meet eligibility criteria — especially based on falsified BMI documentation — is a prescribing violation that can result in license action.

Section 2: Compounding and Drug Sourcing Compliance

✅ Branded GLP-1 Medications in Use

Following the FDA's shortage resolution, practices should be using FDA-approved branded medications: Wegovy or Ozempic (semaglutide), Zepbound or Mounjaro (tirzepatide). If you are still using compounded GLP-1s from a 503A pharmacy, document the patient-specific clinical justification for every patient — or transition immediately to branded products.

✅ Pharmacy Vendor Verification

Verify that any pharmacy supplying your GLP-1 medications is:

• Licensed in your state
• NABP-accredited (503A retail pharmacies) or FDA-registered (503B outsourcing facilities)
• Not appearing on FDA warning letter lists or state pharmacy board violation records
• Supplying only medications with lot number and expiration date documentation

✅ Medication Storage Compliance

GLP-1 medications require refrigeration (36–46°F). Your storage compliance checklist should include:

• Dedicated pharmaceutical refrigerator with temperature logging
• Twice-daily temperature checks documented
• Defined response protocol for temperature excursions
• No co-mingling of medications with food or non-pharmaceutical items

Section 3: Documentation and Record-Keeping

✅ Comprehensive Patient Chart for Each Visit

Every patient interaction must be documented. Weight loss chart entries should include:

• Current weight, BMI change since last visit
• Blood pressure and heart rate
• Side effect assessment (GI symptoms, injection site reactions)
• Current dose and any dose changes with rationale
• Refill authorization (prescriber name and signature or electronic authorization)
• Patient compliance with lifestyle modifications
• Next scheduled appointment

✅ Signed Informed Consent on File

A current, dated informed consent must be in every patient's chart. The consent should disclose:

• FDA-approved indications and off-label use disclosure if applicable
• Boxed Warning about thyroid C-cell tumors (for all GLP-1 medications)
• Common side effects (nausea, vomiting, diarrhea, constipation, injection site reactions)
• Serious risks (pancreatitis, gallbladder disease, hypoglycemia if diabetic)
• Pregnancy risk and requirement to discontinue before conception
• Cost, refund policy, and non-guarantee of specific weight loss results

✅ Prescription Records

Maintain complete prescription records including: prescriber name, patient name, drug name and manufacturer, dose, quantity dispensed, date, and pharmacy name. If dispensing from office stock, maintain an inventory log documenting receipt and dispensing of each lot number.

Section 4: Monitoring and Follow-Up

✅ Defined Monitoring Protocol in SOP

Your SOP must specify minimum monitoring requirements. Recommended standard:

• Monthly during titration: Clinical check-in (in-person or telehealth), weight/vitals, side effect assessment, dose review
• Every 3 months: Metabolic panel, HbA1c for patients with diabetes or pre-diabetes
• Every 6 months: Comprehensive review, lipid panel, assessment of continued benefit
• Ongoing: Screening for pancreatitis symptoms, gallbladder disease

✅ Discontinuation Criteria Defined

The SOP must specify when treatment should be stopped. Minimum discontinuation criteria:

• Inadequate response (less than 5% weight loss after 16 weeks at therapeutic dose)
• Intolerable side effects
• New contraindication diagnosed
• Pregnancy
• Patient non-compliance with monitoring requirements

Section 5: Marketing Compliance

✅ No Misleading Weight Loss Claims

Your marketing for weight loss services must be accurate and not misleading. Specific requirements:

• Do not promise specific weight loss results (e.g., "lose 40 pounds in 3 months")
• Do not use before/after photos from other practices or stock photos as if they are your patients
• Do not describe compounded medications as equivalent to branded medications
• Include appropriate disclosures for any patient testimonials
• Do not market GLP-1 medications as appropriate for patients who don't meet clinical criteria

✅ FTC Endorsement Guidelines

If using patient testimonials, social media influencer content, or before/after photos in your marketing, comply with FTC endorsement disclosure requirements. Paid or incentivized endorsements must be clearly disclosed.

The Compliance Audit Checklist Summary

Prescribing Foundation:

• ☐ Licensed prescriber on file with current, active license
• ☐ Medical director standing orders signed, dated, and current
• ☐ GFE documented for every patient before first prescription
• ☐ Patient eligibility criteria defined in SOP

Drug Sourcing:

• ☐ Using branded GLP-1 medications or documented patient-specific justification for compounded
• ☐ Pharmacy vendor verified (licensed, accredited, not on warning lists)
• ☐ Medication storage compliant (temp logging, dedicated refrigerator)

Documentation:

• ☐ Visit notes in every patient chart with weight, vitals, side effects, dose rationale
• ☐ Signed informed consent on file with GLP-1 Boxed Warning disclosures
• ☐ Prescription records maintained

Monitoring:

• ☐ Monthly monitoring during titration (documented)
• ☐ Quarterly and semi-annual lab review protocol in SOP
• ☐ Discontinuation criteria defined and documented